A Pilot Study to Evaluate the PhageTech Virus BioResistor inDetecting Combinations of Bladder Cancer Biomarkers inPatients Under Active BCa Surveillance

To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.

Start Date08 Feb 2021

Sponsor / Collaborator

PhageTech, Inc.

100 Clinical Results associated with PhageTech, Inc.

0 Patents (Medical) associated with PhageTech, Inc.

Literatures (Medical) associated with PhageTech, Inc.

27 Sep 2023·Clinical Chemistry

B-278 Pilot Clinical Study of the CarePoint Assay

Author: Scarpato, K R ; Briggs1, J S ; Linehan, J ; Bassett, J C ; Elenberger, T J ; Brenneman, R ; Chang, S S ; Brooks-Starks, A H

AbstractBackgroundAn estimated >710 000 individuals live with bladder cancer in the United States, with approximately 82 290 new cases expected this year (2023). Recurrence rates for bladder cancer are high: approximately 65% of patients with non-invasive or in situ tumors and 73% of patients with more advanced disease experience recurrence within five years. Consequently, patients treated for bladder cancer require prolonged surveillance to safeguard against tumor recurrence. The gold standard of surveillance, cystoscopy—an uncomfortable, expensive, and invasive procedure—is recommended every three to 12 months. Consequently, there is a need for an inexpensive, effective, noninvasive diagnostic tool as an alternative to cystoscopy.The CarePoint Assay (CPA) is a 30-minute electrochemical immunoassay for the detection of disease-state biomarkers in human urine. The analytical performance of CPA has been evaluated for method comparison with a three-hour sandwich immunosorbent assay (ELISA) for bladder tumor antigen (BTA), a diagnostic biomarker for bladder cancer.MethodReceiver operating characteristic (ROC) curves were calculated by simple logistic regression with Prism9 (GraphPad) using patient urine samples across multiple medical centers (n = 51), comparing BTA concentration (continuous variable) with high-grade tumor status (binary variable). Patient urine samples were evaluated by CPA using commercial potentiostats for comparison with a sandwich ELISA. The data was analyzed using simple linear regression.ResultsPatient urine evaluated by CPA was interpolated by simple linear regression using a three-point calibration with standard spiked into urine pooled from healthy donors. Data produced by sandwich ELISA was interpolated by five-parameter nonlinear regression using a 12-point standard curve. Both methods showed good correlation: (r) = 0.93. Simple logistic regression comparing analyte concentration to high-grade tumor status produced a sensitivity and specificity of 52% and 88% with an AUROC of 0.71 for the CPA, and a sensitivity and specificity of 72% and 77% with an AUROC of 0.77 for the sandwich ELISA. Sensitivities and specificities were calculated using Youden’s J statistic.ConclusionsWe established proof of concept for a rapid, electrochemical immunoassay for a diagnostic biomarker of bladder cancer. The CPA correlated well with sandwich ELISA, an established method for measuring biomarkers in bodily fluids. Future work will focus on refinement of the CPA architecture for point-of-care use and subsequent evaluation of analytical performance.

01 Feb 2004·Nature Biotechnology

Antimicrobial drug discovery through bacteriophage genomics

Article

Author: Moeck, Greg ; Williams, Dan ; Ha, Nhuan ; DuBow, Michael ; Bauda, Pascale ; Liu, Jing ; Bergeron, Dominique ; McCarty, John ; Kwan, Tony ; Callejo, Mario ; Gros, Philippe ; Pelletier, Jerry ; Ferretti, Vincent ; Dehbi, Mohammed ; Wu, Jinzi J. ; Srikumar, Ramakrishnan ; Arhin, Francis

Over evolutionary time bacteriophages have developed unique proteins that arrest critical cellular processes to commit bacterial host metabolism to phage reproduction. Here, we apply this concept of phage-mediated bacterial growth inhibition to antibiotic discovery. We sequenced 26 Staphylococcus aureus phages and identified 31 novel polypeptide families that inhibited growth upon expression in S. aureus. The cellular targets for some of these polypeptides were identified and several were shown to be essential components of the host DNA replication and transcription machineries. The interaction between a prototypic pair, ORF104 of phage 77 and DnaI, the putative helicase loader of S. aureus, was then used to screen for small molecule inhibitors. Several compounds were subsequently found to inhibit both bacterial growth and DNA synthesis. Our results suggest that mimicking the growth-inhibitory effect of phage polypeptides by a chemical compound, coupled with the plethora of phages on earth, will yield new antibiotics to combat infectious diseases.

100 Deals associated with PhageTech, Inc.

100 Translational Medicine associated with PhageTech, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Jun 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PhageTech, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 24 Jun 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing